Search

Your search keyword '"Howes O"' showing total 405 results
Start Over Author "Howes O" Language english
405 results on '"Howes O"'

1. CLEAR – clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings

Author

Casetta, C., Santosh, P., Bayley, R., Bisson, J., Byford, S., Dixon, C., Drake, R. J., Elvins, R., Emsley, R., Fung, N., Hayes, D., Howes, O., James, A., James, K., Jones, R., Killaspy, H., Lennox, B., Marchant, L., McGuire, P., Oloyede, E., Rogdaki, M., Upthegrove, R., Walters, J., Egerton, A., and MacCabe, J. H.

Published
2024
Full Text
View/download PDF

20. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

Author

Eap, C.B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Dahl, M.L., de Leon, J., Greiner, C., Howes, O., Kim, E., Lanzenberger, R., Meyer, J.H., Moessner, R., Mulder, H., Müller, D.J., Reis, M., Riederer, P., Ruhe, H.G., Spigset, O., Spina, E., Stegman, B., Steimer, W., Stingl, J., Suzen, S., Uchida, H., Unterecker, S., Vandenberghe, F., and Hiemke, C.

Subjects
Antidepressants, brain imaging, pharmacogenetics, precision medicine, therapeutic drug monitoring
Abstract

Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient.Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic drug monitoring) and genotype relevant genetic polymorphisms of enzymes, transporters or receptors involved in drug metabolism or mechanism of action. Imaging studies, primarily positron emission tomography that relates drug concentrations in blood and radioligand binding, are considered to quantify target structure occupancy by the antidepressant drugs in vivo. Results: Evidence is given that in vivo imaging, therapeutic drug monitoring and genotyping and/or phenotyping of drug metabolising enzymes should be an integral part in the development of any new antidepressant drug.Conclusions: To guide antidepressant drug therapy in everyday practice, there are multiple indications such as uncertain adherence, polypharmacy, nonresponse and/or adverse reactions under therapeutically recommended doses, where therapeutic drug monitoring and cytochrome P450 genotyping and/or phenotyping should be applied as valid tools of precision medicine.

Published
2021

26. Correction: Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study (Molecular Psychiatry, (2021), 10.1038/s41380-021-01108-y)

Author

Rogdaki, M., Devroye, C., Ciampoli, M., Veronese, M., Ashok, A. H., Mccutcheon, R. A., Jauhar, S., Bonoldi, I., Gudbrandsen, M., Daly, E., van Amelsvoort, T., Van Den Bree, M., Owen, M. J., Turkheimer, F., Papaleo, F., and Howes, O. D.

Published
2021

32. J Psychiatry Neurosci

Author

SISKIND, D., HONER, W. G., Clark, S., CORRELL, C. U., Hasan, A., HOWES, O., KANE, J. M., KELLY, D. L., LAITMAN, R., Lee, J., MACCABE, J. H., MYLES, N., Nielsen, J., SCHULTE, P. F., Taylor, D., VERDOUX, Helene, Wheeler, A., FREUDENREICH, O., Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
PharmacoEpi-Drugs, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Published
2020
Full Text
View/download PDF

34. Randomised control trial of the effectiveness of an integrated psychosocial health promotion intervention aimed at improving health and reducing substance use in established psychosis (IMPaCT)

Author

Gaughran, F., Stahl, D., Ismail, K., Greenwood, K., Atakan, Z., Gardner-Sood, P., Stubbs, B., Hopkins, D., Patel, A., Lally, J., Lowe, P., Arbuthnot, M., Orr, D., Corlett, S., Eberhard, J., David, A. S., Murray, R., Smith, S., Harries, B., Moore, S., Bonaccorso, S., Kolliakou, A., O'Brien, C., Featherman, A., Fung, C., Heslin, M., Dalemo, K., Anakwe-Umeh, S., Todd, G., Mushore, M., Mutsatsa, S., Howes, O., Ohlsen, R., Papanastasiou, E., Firdosi, M., Sallis, H., Sambath, I., Di Clemente, G., Breedvelt, J., Joseph, C., Di Forti, M., Odesanya, A., Onagbesan, D., Case, P., Musa, A., Dalton, C., Antionades, H., Reece, B., Healy, A., Sinan, F., Rudhra, K., Kelly, H., Treasure, J., Davis, A., Murphy, C., Kelly, J., and Goldin, M.

Subjects
Adult, Male, Quality of life, medicine.medical_specialty, Randomization, Substance-Related Disorders, lcsh:RC435-571, Cost-Benefit Analysis, Psychological intervention, Health Promotion, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Surveys and Questionnaires, lcsh:Psychiatry, Health care, Humans, Psychology, Medicine, 030212 general & internal medicine, Mortality, Aged, business.industry, Middle Aged, medicine.disease, Psychosis, Mental health, 030227 psychiatry, Psychiatry and Mental health, Mental Health, Treatment Outcome, Health promotion, Psychotic Disorders, Schizophrenia, Physical therapy, Female, business, Health promotion intervention, Psychosocial, Research Article
Abstract

People with psychosis have a reduced life expectancy of 10–20 years, largely due to cardiovascular disease. This trial aimed to determine the effectiveness of a modular health promotion intervention (IMPaCT Therapy) in improving health and reducing cardiovascular risk in psychosis. A multicentre, two arm, parallel cluster RCT was conducted across five UK mental health NHS trusts. Community care coordinators (CC) were randomly assigned to training and supervision in delivering IMPaCT Therapy or treatment as usual (TAU) to current patients with psychosis (cluster). The primary outcome was the physical and mental health subscales of the Short form-36 (SF-36) questionnaire. Of 104 care coordinators recruited, 52 (with 213 patients) were randomised to deliver IMPaCT therapy and 52 (with 193 patients) randomised to TAU. Of 406 patients, 318 (78%) and 301 (74%) attended 12- and 15-month follow-up respectively. IMPaCT therapy showed no significant effect on the physical or mental health component SF-36 scores versus TAU at 12 or 15 months. No effect was observed for cardiovascular risk indicators, except for HDL cholesterol, which improved more with IMPACT therapy than TAU (Treatment effect (95% CI); 0.085 (0.007 to 0.16); p = 0.034). The 22% of patients who received >180 min of IMPACT Therapy in addition to usual care achieved a greater reduction in waist circumference than did controls, which was clinically significant. Training and supervising community care coordinators to use IMPaCT therapy in patients with psychosis is insufficient to significantly improve physical or mental health quality of life. The search for effective, pragmatic interventions deliverable in health care services continues. The trial was retrospectively registered with ISRCTN registry on 23/4/2010 at ISRCTN58667926 ; recruitment started on 01/03/2010 with first randomization on 09.08.2010 ISRCTN58667926 .

Published
2017
Full Text
View/download PDF

49. Neuroimaging in the At Risk Mental State: SP11.2

Author

McGuire, P, Fusar-Poli, F, Borgwardt, S, Allen, P, Valli, I, Broome, M, Woolley, J, Howes, O, Grasby, P, Stone, J, Roiser, J, Valmaggia, L, Mechelli, A, Williams, S, and Barker, G

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results